Thus, IL-6 is considered as a robust driving force for CVD in CKD patients, however, approaches using anti-inflammatory pharmacotherapy have not been convincing to date and clinical studies of targeting of IL-6 are still at the beginning (Huck et al., 2023). This evidence concerns the gene IL6 and chronic kidney disease.